Original language | English (US) |
---|---|
Pages (from-to) | 184-188 |
Number of pages | 5 |
Journal | British Journal of Haematology |
Volume | 186 |
Issue number | 1 |
DOIs | |
State | Published - Jul 2019 |
Keywords
- chronic lymphocytic leukaemia
- genomic risk factors
- ibrutinib
- tumour debulking
- tumour lysis syndrome risk
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: British Journal of Haematology, Vol. 186, No. 1, 07.2019, p. 184-188.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia
AU - Wierda, William G.
AU - Byrd, John C.
AU - O'Brien, Susan
AU - Coutre, Steven
AU - Barr, Paul M.
AU - Furman, Richard R.
AU - Kipps, Thomas J.
AU - Burger, Jan A.
AU - Stevens, Don A.
AU - Sharman, Jeff
AU - Ghia, Paolo
AU - Flinn, Ian W.
AU - Zhou, Cathy
AU - Ninomoto, Joi
AU - James, Danelle F.
AU - Tam, Constantine S.
N1 - Funding Information: We thank the patients who participated in these studies and their supportive families, as well as the investigators and clinical research staff from the study centres. These studies were sponsored by Pharmacyclics LLC, an AbbVie Company. James P. Dean, MD, PhD, an employee of Pharmacyclics LLC, an AbbVie Company, contributed to manuscript development and data interpretation. Medical writing support was provided by Danielle Ippolito, PhD, CMPP, and funded by Pharmacyclics LLC, an AbbVie Company. JCB was supported by R35 CA197734 (this funding is independent of the current studies in the pooled analysis). Funding Information: WGW received research funding from AbbVie, Genentech and Pharmacyclics LLC, an AbbVie Company. JCB received research funding from Acerta, Genentech, Janssen and Phar-macyclics LLC, an AbbVie Company. SO served in a consultancy/advisory role with AbbVie, Alexion, Amgen, Aptose Biosciences, Inc., Astellas, Celgene, Gilead, GlaxoSmithKline, Janssen Oncology, Pfizer, Pharmacyclics LLC, an AbbVie Company, Sunesis, TG Therapeutics and Vaniam Group LLC; and received research funding from Acerta, Gilead, Kite, Pfizer, Pharmacyclics LLC, an AbbVie Company, Regeneron, Sunesis and TG Therapeutics. SEC received honoraria from Janssen and Pharmacyclics LLC, an AbbVie Company; served in a consultancy/advisory role for AbbVie, BeiGene and Janssen; and received research funding from AbbVie, Acerta, Gilead, Janssen and Pharmacyclics LLC, an AbbVie Company. PMB served in a consultancy/advisory role for AbbVie, Celgene, Novartis, Genentech, Verastem, Gilead, Merck and Seattle Genetics. RRF served in a consultancy/advisory role for AbbVie, Janssen, Gilead, Sunesis, TG Therapeutics, Verastem, Genentech and Pharmacyclics LLC, an AbbVie Company. TJK served in a consultancy/advisory role for AbbVie, Genentech-Roche, Gilead, Celgene and Pharma-cyclics LLC, an AbbVie Company, and received research funding from AbbVie, Genentech-Roche, Oncternal and Pharmacyclics LLC, an AbbVie Company. JAB received honoraria and travel expenses from Janssen; served in a consultancy/advisory role for Gilead, Janssen and Pharmacyclics LLC, an AbbVie Company; and received research funding from Pharmacyclics LLC, an AbbVie Company. DAS served in a consultancy/advisory role with Bayer. JS served in a consultancy/advisory role and received research funding from Acerta, Celgene, Genentech, Gilead, AbbVie, TG Therapeutics and Pharmacyclics LLC, an AbbVie Company. PG received honoraria and served in a consultancy/advisory role for Abb-Vie, Acerta, BeiGene, Gilead, Janssen, Roche and Sunesis; received research funding from AbbVie, Gilead, Janssen, and Novartis, and served on the speakers bureau for Gilead. IWF’s institution received research funding from Agios, ArQule, Beigene, Calithera, Celgene, Constellation, Curis, Forma, Forty Seven, Genentech, Gilead, Incyte, Infinity, Jans-sen, Kite, Merck, Novartis, Pfizer, Pharmacyclics LLC, an AbbVie Company, Portola, Seattle Genetics, Takeda, TG Therapeutics, Trillium and Verastem. CZ is employed with Pharmacyclics LLC, an AbbVie Company and has stock ownership in AbbVie. JN is employed with Pharmacyclics LLC, an AbbVie Company and has stock ownership in AbbVie, Amgen and Celgene. DFJ is employed with Pharmacyclics LLC, an AbbVie Company; husband is employed with Abb-Vie; has stock ownership in AbbVie; husband has stock ownership in AbbVie, and has patents/royalties/other intellectual property with AbbVie. CST received honoraria, served in a consultancy/advisory role and received research funding from Janssen.
PY - 2019/7
Y1 - 2019/7
KW - chronic lymphocytic leukaemia
KW - genomic risk factors
KW - ibrutinib
KW - tumour debulking
KW - tumour lysis syndrome risk
UR - http://www.scopus.com/inward/record.url?scp=85061447149&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061447149&partnerID=8YFLogxK
U2 - 10.1111/bjh.15791
DO - 10.1111/bjh.15791
M3 - Letter
C2 - 30740654
AN - SCOPUS:85061447149
SN - 0007-1048
VL - 186
SP - 184
EP - 188
JO - British Journal of Haematology
JF - British Journal of Haematology
IS - 1
ER -